Modified carfilzomib dosing is associated with improved treatment responses and longer time on treatment in patients with multiple myeloma

• Abdullah M. Khan,
• Kiatlyn Dvorak,
• Qiuhong Zhao,
• Naresh Bumma,
• Francesca Cottini,
• Srinivas Devarakonda,
• Elvira Umyarova,
• Nidhi Sharma,
• Don Benson,
• Ashley Rosko

Affiliations

Abdullah M. Khan

Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210

Kiatlyn Dvorak

Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210

Qiuhong Zhao

Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210

Naresh Bumma

Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210

Francesca Cottini

Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210

Srinivas Devarakonda

Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210

Elvira Umyarova

Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210

Nidhi Sharma

Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210

Don Benson

Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210

Ashley Rosko

Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210